Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 42.66 USD -0.86%
Market Cap: 261.1m USD

EV/EBIT
Enterprise Value to EBIT

-11.7
Current
-6.5
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-11.7
=
Enterprise Value
206.3m USD
/
EBIT
-17.7m USD
EBIT Growth EV/EBIT to Growth
US
Monopar Therapeutics Inc
NASDAQ:MNPR
Average EV/EBIT: 20.8
Negative Multiple: -11.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 909.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -549.3 N/A N/A
AU
CSL Ltd
ASX:CSL
23.6
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -433 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-28.2
2-Years Forward
EV/EBIT
-12.4
3-Years Forward
EV/EBIT
-8.6